TSC-100

Cell therapy

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (1)
Hematologic Malignancies

Competitive landscape

This drug's own stage for Hematologic Malignancies: Phase 1. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
TSC-100: this drugPhase 1Cell therapyHA-1 minor histocompatibility antigen (HLA-A*02:01)not yet gradedNo reviewed efficacy summary in this indication
TSC-101Phase 3Cell therapyHA-2 (minor histocompatibility antigen)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.